Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

开始日期2024-03-20

申办/合作机构

Bayer AG

[+3]

NCT05688436

/ RecruitingN/A

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

The primary objective of the study is to estimate the prevalence of major congenital malformations (MCMs) and compare the prevalence between the diroximel fumarate (DRF) and comparator groups. The secondary objectives of the study are to estimate the incidence of spontaneous abortion (SA) and compare the incidence between the DRF and comparator groups; to estimate the incidence of preterm birth and compare the incidence between the DRF and comparator groups; to estimate the incidence of stillbirth and compare the incidence between the DRF and comparator groups and to estimate the prevalence of small for gestational age (SGA) and compare the prevalence between the DRF and comparator groups.

开始日期2021-09-24

申办/合作机构

Biogen, Inc.

NCT04079088

/ Withdrawn临床2期

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS.
The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.

开始日期2021-06-30

申办/合作机构

Biogen, Inc.

100 项与聚乙二醇干扰素β-1a 相关的临床结果

登录后查看更多信息

100 项与聚乙二醇干扰素β-1a 相关的转化医学

登录后查看更多信息

100 项与聚乙二醇干扰素β-1a 相关的专利（医药）

登录后查看更多信息

104

项与聚乙二醇干扰素β-1a 相关的文献（医药）

2025-02-01·Multiple Sclerosis and Related Disorders

Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies

Review

作者: Śladowska, Katarzyna ; Brzostek, Tomasz ; Moćko, Paweł ; Kawalec, Paweł

OBJECTIVEThis study aimed to review the efficacy and safety profile of disease-modifying therapies (DMTs) in patients with relapsing pediatric-onset multiple sclerosis (POMS).METHODSA systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Published randomized controlled trials (RCTs), nonrandomized studies with a control group, large single-arm studies, and ongoing (unpublished) studies investigating the use of approved and unapproved DMTs in POMS were included. Eligible published studies were identified in MEDLINE (via PubMed), EMBASE, and the Cochrane Library, and unpublished studies were identified in a clinical trials registry (www.CLINICALTRIALSgov).RESULTSA total of 13 published studies were included in the systematic review: 4 RCTs, 3 observational studies with a control group, and 6 large single-arm studies. The following DMTs for the treatment of POMS were evaluated in the included studies: interferon beta-1a, interferon beta-1b, teriflunomide, dimethyl fumarate, fingolimod, natalizumab, glatiramer acetate, and ocrelizumab. All DMTs were shown to be effective in reducing relapse rates, preventing disability progression, and reducing disease activity in MRI in patients with POMS. DMTs that are considered highly effective in adults with multiple sclerosis (natalizumab, fingolimod) were also shown to be more effective than interferon beta-1a in POMS. A total of 9 ongoing (unpublished) studies were identified, including 5 RCTs. The following drugs were evaluated: ozanimod, fingolimod, peginterferon beta-1a, ocrelizumab, ofatumumab, siponimod, alemtuzumab, and natalizumab.CONCLUSIONThe number of DMTs approved for the treatment of POMS is limited, and some of the available DMTs are used off-label. The available evidence from published studies of varying reliability supports the efficacy of DMTs in POMS. However, well-designed, long-term RCTs in the pediatric population are needed. The results of ongoing studies may fill the existing gap in clinical evidence, possibly leading to the approval of more highly effective DMTs for patients with POMS.

2024-10-01·Multiple Sclerosis and Related Disorders

Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)

Article

作者: Ashtari, Fereshteh ; Saeidi, Morteza ; Shaygannejad, Vahid ; Abolfazli, Roya ; Ayromlou, Hormoz ; Baghbanian, Seyed Mohammad ; Asadollahzadeh, Elnaz ; Beladi Moghadam, Nahid ; Sabzvari, Araz ; Ghiasian, Masoud ; Ghalyanchi Langroodi, Hamidreza ; Azimi Saeen, Amirreza ; Kafi, Hamidreza

BACKGROUNDMultiple sclerosis (MS) is a prevalent, disabling, inflammatory, neurodegenerative disease that typically manifests during a highly productive stage of life. Interferon beta-1a was among the first approved disease-modifying therapies for MS and remains among the first-line treatment options. Pegylation of the interferon beta-1a molecule prolongs its half-life while maintaining its efficacy and safety profile. In PEGINTEGRITY study, we aimed to compare peginterferon beta-1a with interferon beta-1a in terms of efficacy and safety in relapsing-remitting multiple sclerosis (RRMS) patients.METHODSThis study was a randomized, active-controlled, parallel-group, multi-center Phase 3 trial conducted in Iran in participants with RRMS. Participants received 125 µg of subcutaneous peginterferon beta-1a every two weeks or 30 µg of intramuscular interferon beta-1a once a week for up to 96 weeks. The primary outcome was the non-inferiority of peginterferon beta-1a to interferon beta-1a in reducing annualized relapse rate (ARR). Other outcomes included the number of patients with 12-week confirmed disability progression, the number of new or newly-enlarging T2 hyperintense lesions, the number of gadolinium-enhancing lesions, the number of new T1 hypointense lesions, the volume of new or newly-enlarging T2 hyperintense lesions, changes in brain volume, immunogenicity, and safety assessments.RESULTSA total of 168 patients who met the eligibility criteria were enrolled and assigned to two arms of the study, each consisting of 84 participants. Totally, 41 participants (24 patients in the peginterferon beta-1a group and 17 patients in the interferon beta-1a group) were withdrawn from the study. The withdrawn patients were included in the per-protocol analysis for the period of time they were in the study. In 96 weeks, in the per-protocol population, the ARR was 0.05 in the peginterferon beta-1a group versus 0.11 in the interferon beta-1a group, which does not reflect a statistically significant difference (p=0.09; 95 % CI, 0.18-1.14). Considering the upper limit of the one-sided 95 % CI of the rate ratio of peginterferon beta-1a compared to interferon beta-1a, as well as the non-inferiority margin, it can be concluded that the primary outcome was met. The results were also comparable for other efficacy and safety outcomes.CONCLUSIONThe results demonstrate the non-inferiority of peginterferon beta-1a to interferon beta-1a with similar efficacy in 96-week ARR in RRMS patients. Both arms were also comparable in other efficacy outcomes and safety profiles with no statistically significant differences. These findings support considering peginterferon beta-1a as a safe and efficient option in patients with RRMS. This study was registered on Iranian Registry of Clinical Trials (IRCT201612306135N8) and clinicaltrials.gov (NCT05242133).

2024-04-01·Multiple Sclerosis Journal - Experimental, Translational and Clinical

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program

Article

作者: Kumar, Achint ; Salvetti, Marco ; Nelles, Gereon ; Vignos, Megan ; Koster, Thijs ; Belviso, Nicholas ; Wray, Sibyl ; Castro-Borrero, Wanda

Background Interferon beta-1a remains an important treatment option for multiple sclerosis, particularly when safety or tolerability concerns may outweigh the benefits of higher-efficacy disease-modifying therapies. The five-year phase 4 Plegridy Observational Program (POP) study (NCT02230969) collected data on real-world safety and effectiveness of Plegridy® (peginterferon beta-1a) treatment in patients with relapsing multiple sclerosis. Objective To explore the real-world safety and effectiveness of peginterferon beta-1a in patients with relapsing multiple sclerosis, including factors influencing treatment discontinuation. Methods Data were collected prospectively from patients ≥ 18 years old with relapsing multiple sclerosis for overall population analysis and for subpopulations including newly/previously diagnosed patients, age, and experience with peginterferon beta-1a. Outcome measures included annualized relapse rates, adverse events, and predictors of time to treatment discontinuation. Results Mean (SD) treatment duration in the overall population ( N = 1172) was 896.0 (733.15) days. Incidence of adverse events was higher in new than experienced users (79.4% vs. 57.0%). New users were more likely than experienced users to discontinue (hazard ratio = 1.60; P < 0.0001). The adjusted annualized relapse rate was 0.09, and at the end of 5 years, 77.1% of patients were relapse-free. Conclusions Peginterferon beta-1a is an effective therapy for managing relapsing multiple sclerosis. The identification of predictors of discontinuation can help inform strategies to enhance treatment persistence.

项与聚乙二醇干扰素β-1a 相关的新闻（医药）

2025-03-31

·Pharma CMC

创新药 “爆发” 获批！今日85个上市申请获NMPA批准

刚刚，NMPA发布2025年03月31日药品批准证明文件送达信息，本批次共有85个受理号获批，均为上市申请，其中多款创新药获批：此前，NMPA公告过的：宜昌东阳光长江药业的艾考磷布韦片获批上市，用于与磷酸萘坦司韦胶囊联用，治疗初治或干扰素经治的基因1、2、3、6型成人慢性丙型肝炎病毒（HCV）感染，可合并或不合并代偿性肝硬化。江西科睿药业申报的玛舒拉沙韦片获批上市，用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。恒瑞医药的硫酸艾玛昔替尼片获批上市，用于治疗对一种或多种TNF抑制剂疗效不佳或不耐受的活动性强直性脊柱炎成人患者。此外，参天制药的他氟噻吗滴眼液获批上市，推测适应症为：用于降低开角型青光眼或高眼压症成年患者的眼压（IOP），用于对局部单独使用β-受体阻滞剂或前列腺素衍生物疗效不佳而需要联合治疗的患者。他氟噻吗滴眼液是不含防腐剂的0.0015%他氟前列素和0.5%马来酸噻吗洛尔固定剂量复方滴眼液，含有两种对房水动力学有不同作用机制的有效成分，每日滴眼1次即可达到与联合用药相同的有效性和安全性。罗氏的奥瑞利珠单抗注射液（罗可适®）获批上市，每六个月静脉输注一次给药，用于治疗成人复发型多发性硬化症（RMS，包括临床孤立综合征、复发缓解型多发性硬化和活动性继发进展型多发性硬化）和成人原发进展型多发性硬化症（PPMS）。奥瑞利珠单抗是罗氏开发的靶向CD20阳性B细胞的单抗药物。针对复发型多发性硬化症（RMS）的两项随机、双盲、双模拟、阳性药物对照III期临床试验OPERA I和OPERA II结果显示，与干扰素β-1a治疗相比，奥瑞利珠单抗可以显著降低患者的年复发率（ARR）及致残比例（12周确认残疾进展CDP的患者比例）。优时比的罗泽利昔珠单抗注射液获批上市，用于治疗重症肌无力（gMG）。公开资料显示，罗泽利昔珠单抗是一款靶向人类胎儿Fc受体（FcRn）的单克隆抗体，此前已在美国、欧盟、日本等地区获批用于治疗全身性重症肌无力成人患者。百时美施贵宝旗下两款肿瘤免疫治疗药物——欧狄沃（纳武利尤单抗注射液）与逸沃(伊匹木单抗注射液）的联合疗法获批新适应症，用于不可切除或晚期肝细胞（HCC）成人患者的一线治疗，这是中国首个且目前唯一获批的肝细胞癌一线双免疫联合疗法。此次获批基于I期CheckMate-9DW研究，该研究在全球范围内首次证实免疫治疗方案用于肝细胞癌一线治疗，疗效可显著优于两种既往标准治疗药物(仑伐替尼或索拉非尼）。有关研究数据证实：双免方案不仅缓解率高，而且一旦起效，缓解持续时间（DOR）和总生存期（OS）都显著延长。完整批件信息如下：

上市批准临床3期临床2期

2024-11-09

·药事纵横

6家专注于多发性硬化症治疗的biotech

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。多发性硬化症是中枢神经系统（CNS）的一种慢性疾病。作为一种不可预测的疾病，对人的影响不同，一些多发性硬化症患者可能只有轻微的症状，而另一些患者可能会在大脑与身体其他部位之间的交流中断时失去清晰地看、写、说或走路的能力。以下是六家专注于多发性硬化症的生物技术公司，几家公司和研究人员试图通过不同的方法来治疗多发性硬化症，比如BTK抑制剂、CAR-T疗法、双特异性抗体，甚至干细胞疗法。 Biogen 主要多发性硬化候选药物：BIIB091 Biogen以其在神经科学领域的开创性工作而闻名。40多年来，它一直在发现和开发中枢神经系统疾病的治疗方法，包括多发性硬化、肌萎缩侧索硬化（ALS）、阿尔茨海默病、抑郁症、狼疮和脊髓性肌萎缩（SMA）的治疗方法。至于多发性硬化症，该公司已经有几种已获批准的治疗方法，包括Avonex、Plegridy和Vumerity，这些药物都用于治疗多发性硬化症的复发。此外，在其现有的研发过程中，百健正致力于开发下一代伯顿酪氨酸激酶（BTK）抑制剂，称为BIIB091，用于复发性多发性硬化成人患者。目前正处于开发的第二阶段。 BTK是一种非受体酪氨酸激酶，可调节被认为与多发性硬化发病机制有关的B细胞和髓样细胞的发育和信号传导。BIIB091除对B细胞产生作用外，还对髓系细胞中的BTK产生可逆性抑制作用，因此预计BIIB091与仅B细胞疗法相比具有更多的临床益处，并且可以解决共价BTK抑制剂中观察到的耐药性。 Immunic Therapeutics 主要多发性硬化候选药物：Vidofludimus calcium immunictherapeutics正致力于慢性炎症性和自身免疫性疾病的小分子疗法的开发。其主要候选药物是vidofludimus calcium（IMU-838），目前正在开发用于治疗多发性硬化。 IMU-838通过有效激活称为核受体相关1 （Nurr1）的神经保护转录因子发挥作用，Nurr1与直接的神经保护特性相关，并可能增强患者的潜在获益。IMU-838还抑制二氢乳清酸脱氢酶（DHODH），后者是过度活跃的免疫细胞和病毒感染细胞代谢的关键酶。这一双重作用不仅针对炎症和抗病毒过程，而且还解决了多发性硬化潜在的神经退行性方面，使其从现有疗法中脱颖而出，现有疗法虽然能够控制多发性硬化的复发，但不能阻止患者的残疾随着时间的推移而恶化。数项正在进行的多发性硬化试验正在对IMU-838进行测试，包括复发性多发性硬化的两项3期试验和进展性多发性硬化的支持性2期试验。2023年10月，Immunic报告了2期试验的阳性中期数据，因为有生物标志物证据表明，IMU-838的活性超出了之前观察到的抗炎作用。最终，这进一步加强了它的神经保护潜力。此外，在2024年1月，Immunic宣布了高达2.4亿美元的私募。 Kyverna Therapeutics 主要多发性硬化候选药物：KVY-101 Kyverna Therapeutics公司正致力于开发针对b细胞驱动的自身免疫性疾病患者的细胞疗法。这家多发性硬化症公司拥有靶向CD19的自体和异体CAR化合物，该分子在B淋巴细胞的发育、激活和分化中起着重要作用，旨在减少细胞因子释放，消耗B细胞，提高临床耐受性。其主要候选药物KYV-101目前正在一项2期试验中评估用于治疗多发性硬化以及重症肌无力。今年1月，它被美国食品药品监督管理局（FDA）授予快速通道认定，用于治疗难治性进行性多发性硬化患者。此外，Kyverna在2024年2月通过首次公开发行（IPO）获得了.66亿美元的总收益。 Progentos Therapeutics 几个月前，Progentos Therapeutics才成立，获得了6500万美元的A轮融资，用于推进多发性硬化和其他退行性疾病的治疗。在多发性硬化症等疾病中，残疾是由支持轴突功能和生存的脱髓鞘（即髓鞘受损）引起。在这里，免疫系统攻击髓鞘，导致炎症和神经细胞功能受损。正因为如此，Progentos正在开发一种新型小分子，旨在诱导多发性硬化影响的轴突的髓鞘再生。该公司从麻省理工学院（MIT）的子公司Frequency Therapeutics收购了多发性硬化症项目，后者于2023年与RNA编辑公司Korro Bio进行了反向合并。根据Progentos的说法，当涉及到产生和维持髓磷脂的细胞时，它的分子在动物模型中似乎比以前的方法表现更好。从多发性硬化症公司最近的A轮融资中获得的资金将使其能够通过人体概念验证研究来推进其多发性硬化症项目，并扩大其在其他退行性疾病中的研发渠道。 TG Therapeutics 主要多发性硬化候选药物：ublituximab TG Therapeutics专注于利用b细胞生物学的科学进步为患者开发新的治疗方法，特别专注于开发自身免疫性疾病的治疗方法。该公司于2022年12月宣布，FDA已批准其药物BRIUMVI （ublituximab）用于治疗复发型多发性硬化症患者，包括临床孤立综合征，复发缓解性疾病和活动性继发进行性疾病。此外，在2024年9月，TG Therapeutics报告说，经过5年的BRIUMVI治疗，92%的复发性多发性硬化症患者无残疾进展。 Ublituximab是一种单克隆抗体，靶向表达cd20的b细胞上的一个独特表位。当药物与b细胞结合时，会触发一系列免疫反应，包括抗体依赖性细胞毒性[ADCC]和补体依赖性细胞毒性[CDC]，最终导致细胞破坏。此外，阿妥昔单抗被设计为缺乏抗体上正常表达的某些糖分子，因为去除这些糖分子（称为糖工程的过程）已被证明可增强阿妥昔单抗的效力，特别是在ADCC活性方面。作为与Precision BioSciences合作的一部分，TG Therapeutics还在开发一种名为azer-cel的同种异体CAR-T疗法，用于治疗进展型多发性硬化症。Precision BioSciences发现并授权给TG Therapeutics的这一候选药物最近获得了试验性新药（IND）许可，有望于今年晚些时候开始临床试验。 Zenas BioPharma 主要多发性硬化候选药物：Obexelimab Zenas BioPharma专注于基于免疫学的疗法，目前正致力于开发其主要候选药物obexelimab，用于治疗各种免疫学和炎症疾病，包括多发性硬化。 Obexelimab是一种双功能单克隆抗体，旨在通过与广泛存在于B细胞谱系中的蛋白CD19和FcγRIIb结合来耗竭B细胞。根据该公司的说法，这些靶点的共同参与导致了B细胞活性的抑制。 Zenas BioPharma目前正在一项2期试验中纳入患者，以评估obexelimab治疗复发性多发性硬化患者的疗效和安全性。该公司最近也筹集了可观的资金。2024年5月，该公司宣布在C轮融资中获得2亿美元，9月还宣布了2.25亿美元的IPO。这两轮融资的收益将帮助该公司进一步推进obexelimab的研发。参考资料：各公司官网 -END- 2025CMC-CHINA药博会 • 展位火热预定中！

临床2期细胞疗法免疫疗法临床1期临床3期

2024-04-04

·PRNewswire

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

OKLAHOMA CITY, April 4, 2024 /PRNewswire/ -- Cadenza Bio, Inc., a pioneering preclinical biotechnology company dedicated to developing innovative small-molecule drugs for the treatment of multiple sclerosis (MS) and other demyelinating and inflammatory diseases, proudly announces the appointment of Michael A. Panzara, MD, MPH, to its esteemed board of directors. Dr. Panzara brings over 22 years of invaluable biopharmaceutical experience to Cadenza Bio. He currently serves as chief medical officer at Neurvati Neurosciences, a neuroscience-focused biotechnology company working to advance the development of clinical-stage product candidates for neurological and neuropsychiatric disorders. Prior to his role at Neurvati, Dr. Panzara held key leadership positions at Wave Life Sciences, Sanofi, Genzyme, and Biogen, showcasing his deep understanding of neurological disorders and drug development. He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company. Over his career, Dr. Panzara oversaw development activities and global regulatory approvals for several MS drugs. He served as the head of the Multiple Sclerosis, Neurology, and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he oversaw global regulatory approvals of LEMTRADA® (alemtuzumab) and AUBAGIO® (teriflunomide) and was responsible for development strategy and oversight within these therapeutic areas. During his time at Biogen, he served as global clinical lead for the development of TYSABRI® (natalizumab) for MS and managed clinical development activities for all late-stage MS products including AVONEX® (interferon beta-1a), PLEGRIDY® (PEG-interferon beta-1a), and TECFIDERA® (dimethylfumarate). "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, chief executive officer of Cadenza Bio. "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio. Dr. Panzara's strategic insights and deep understanding of the industry will be invaluable as we continue to advance our innovative drug pipeline and work towards bringing transformative treatments to patients in need." Dr. Panzara received his undergraduate degree in biology from the University of Pennsylvania and his medical degree from Stanford University School of Medicine. He completed his neurology training at Massachusetts General Hospital and received postdoctoral training in immunology and rheumatology at Brigham and Women's Hospital. Additionally, Dr. Panzara earned his master of public health degree from the Harvard School of Public Health. With Dr. Panzara joining the board of directors, Cadenza Bio is in a stronger position to achieve its goal of developing groundbreaking therapies for MS and other demyelinating and inflammatory diseases. "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara. "Their approach in developing innovative dual-action therapeutic agents with neuroprotective and immunomodulatory effects has great potential to significantly expand our ability to address the unmet needs that remain for many MS patients." For more information about Cadenza Bio and its groundbreaking research, please visit . About Cadenza Bio, Inc. Cadenza Bio, Inc. is a preclinical biotechnology company focused on developing innovative small-molecule drugs for the treatment of demyelinating and inflammatory diseases. The company's mission is to break the cycle of disease and transform lives by developing therapies that not only alleviate symptoms but also halt progression, promote repair, and restore quality of life for patients. Cadenza Bio's MS drug pipeline, emerging from a collaboration between leading researchers, demonstrates promising preclinical results and offers hope for patients suffering from these debilitating conditions. SOURCE Cadenza Bio, Inc.

高管变更

100 项与聚乙二醇干扰素β-1a 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10483	聚乙二醇干扰素β-1a	L03AB13	DB09122

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多发性硬化症	美国	Biogen, Inc.	2014-08-15
复发-缓解型多发性硬化	欧盟	Biogen Netherlands BV	2014-07-18
复发-缓解型多发性硬化	挪威	Biogen Netherlands BV	2014-07-18
复发-缓解型多发性硬化	冰岛	Biogen Netherlands BV	2014-07-18
复发-缓解型多发性硬化	列支敦士登	Biogen Netherlands BV	2014-07-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性多发性硬化	药物发现	克罗地亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	加拿大	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	加拿大	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	墨西哥	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	哥伦比亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	新西兰	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	哥伦比亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	新西兰	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	克罗地亚	Biogen, Inc.	2009-06-01
复发性多发性硬化	药物发现	墨西哥	Biogen, Inc.	2009-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NPMSC (AAN2024)	N/A	-	254	Avonex	選鬱醖範顧壓廠網鹽構(範憲繭範鏇製夢廠築鬱) = 蓋襯壓糧窪鹹鏇願獵築糧憲選獵壓遞窪窪鹽壓 (觸窪鹹廠糧夢衊繭糧積 ) 更多	积极	2024-04-09
				Plegridy	選鬱醖範顧壓廠網鹽構(範憲繭範鏇製夢廠築鬱) = 遞淵膚築簾網壓襯鑰鹽糧憲選獵壓遞窪窪鹽壓 (觸窪鹹廠糧夢衊繭糧積 ) 更多
PeMSDD (ACTRIMS2024)	N/A	-	254	Avonex	遞醖襯鹹顧糧糧選鹹網(鏇構鑰鹽願觸窪憲壓艱) = 遞窪構範築壓膚醖獵廠繭顧齋繭鑰齋鹽鬱鹽築 (願膚遞糧簾構憲網簾餘 ) 更多	积极	2024-03-01
				Plegridy	遞醖襯鹹顧糧糧選鹹網(鏇構鑰鹽願觸窪憲壓艱) = 網範膚網築願餘夢鏇鹽繭顧齋繭鑰齋鹽鬱鹽築 (願膚遞糧簾構憲網簾餘 ) 更多
NCT03870763 (CTgov)	临床3期	复发-缓解型多发性硬化	11	Dimethyl Fumarate (Dimethyl Fumarate 240 mg)	(醖蓋選鏇襯衊蓋鬱遞選) = 廠願遞鏇窪獵簾繭範鑰築淵醖選糧築遞窪壓鹹 (構鏇願製築蓋餘遞願鹹, 鬱憲餘積襯製淵鑰範鏇 ~ 願憲蓋憲願願餘築選選) 更多	-	2023-05-16
				Peginterferon Beta-1a (Peginterferon Beta-1a 125 µg)	(醖蓋選鏇襯衊蓋鬱遞選) = 網衊繭鏇壓淵製齋夢遞築淵醖選糧築遞窪壓鹹 (構鏇願製築蓋餘遞願鹹, 憲築憲鹽醖簾淵積構顧 ~ 選壓築構製鬱壓膚鏇構) 更多
PRIMA (ECTRIMS2022)	N/A	-	426	Peginterferon beta-1a	鑰鏇憲顧獵壓鏇顧艱築(繭壓膚夢衊製簾鑰願觸) = 遞蓋製壓鬱齋構鬱艱鏇鬱鑰繭製膚顧膚獵衊鏇 (鹹築淵廠遞憲淵遞遞蓋 ) 更多	-	2022-10-12
				Intramuscular IFNβ-1a	鑰鏇憲顧獵壓鏇顧艱築(繭壓膚夢衊製簾鑰願觸) = 淵鹽壓鹽蓋鏇糧願齋構鬱鑰繭製膚顧膚獵衊鏇 (鹹築淵廠遞憲淵遞遞蓋 ) 更多
Plegridy Observational Program (ECTRIMS2021)	N/A	复发性多发性硬化	1,208	Peginterferon beta-1a	繭窪積鬱鬱獵願積醖鬱(鏇顧顧壓膚鑰網醖顧淵) = 餘夢壓衊繭廠膚膚鹹遞夢夢獵獵窪淵積製鏇顧 (餘鏇糧鹹鏇鬱鹽壓壓鬱 ) 更多	积极	2021-10-12
				Placebo	繭窪積鬱鬱獵願積醖鬱(鏇顧顧壓膚鑰網醖顧淵) = 積夢構齋顧襯鏇鬱艱顧夢夢獵獵窪淵積製鏇顧 (餘鏇糧鹹鏇鬱鹽壓壓鬱 ) 更多
IMSE 6 (ECTRIMS2021)	N/A	-	393	Peginterferon beta-1a	(襯糧餘壓積膚繭衊鏇繭) = General disorders and administration site were also the most common for non-serious AEs (68%) 夢窪壓網鬱醖獵廠廠廠 (餘壓淵顧淵網範糧蓋觸 ) 更多	积极	2021-10-12
ECTRIMS2020	N/A	-	-	Peginterferon beta-1a	(餘憲顧膚簾蓋繭獵獵淵): ARR ratio = 1.18 (95% CI, 0.72 ~ 1.94), P-Value = 0.5047 更多	-	2020-12-07
				Non-pegylated interferons
ECTRIMS2020	N/A	多发性硬化症	2,479	Peginterferon beta-1a	鏇構遞遞廠顧顧簾壓壓(憲餘積窪鬱觸網憲壓顧) = 鑰餘衊構鑰鏇範製簾廠鑰遞廠糧製糧觸蓋繭遞 (願鹹壓夢廠齋衊艱蓋鑰 ) 更多	-	2020-12-07
				Intramuscular interferon beta-1a	衊廠憲遞壓遞衊淵鬱觸(鏇醖夢鏇願衊顧餘鬱範) = 艱鑰夢蓋繭鏇衊獵糧鏇築鏇襯鏇積窪窪繭襯願 (襯壓淵鹽鹹蓋鹹襯廠遞 )
NARCOMS (ECTRIMS2020)	N/A	复发性多发性硬化	-	Intramuscular interferon beta-1a	醖鹽餘窪膚夢廠蓋鑰憲(鑰積構願壓壓獵淵壓廠) = 範醖鑰觸範積廠衊鹽簾餘淵築製鏇艱選憲範築 (獵積鬱淵築餘壓膚願觸 ) 更多	积极	2020-12-07
				Peginterferon beta-1a	醖鹽餘窪膚夢廠蓋鑰憲(鑰積構願壓壓獵淵壓廠) = 鹽夢鏇鑰鑰製觸醖襯製餘淵築製鏇艱選憲範築 (獵積鬱淵築餘壓膚願觸 ) 更多
MS PATHS (ECTRIMS2020)	N/A	-	817	Peginterferon beta-1a	顧壓製夢選鏇遞膚醖鹽(積願壓憲觸蓋鏇願淵廠) = 廠鑰遞範糧壓糧膚願製鑰製鬱蓋膚網鹽蓋夢醖 (廠築鹽廠製願網襯遞齋 ) 更多	积极	2020-12-07
				Intramuscular interferon beta-1a	顧壓製夢選鏇遞膚醖鹽(積願壓憲觸蓋鏇願淵廠) = 構壓築鑰衊鹹夢鏇顧繭鑰製鬱蓋膚網鹽蓋夢醖 (廠築鹽廠製願網襯遞齋 ) 更多